^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ABP 206 (nivolumab biosimilar)
i
Other names: ABP 206, ABP-206, ABP206
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Amgen
Drug class:
PD1 inhibitor
Related drugs:
5d
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
P2, N=18, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
Enrollment open
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar) • Voyager-V1
7d
S2107: Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation (clinicaltrials.gov)
P2, N=86, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2026 --> Jun 2027 | Trial primary completion date: Sep 2026 --> Feb 2026
Trial completion date • Trial primary completion date
|
BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
|
BRAF V600E • BRAF V600
|
Opdivo (nivolumab) • Erbitux (cetuximab) • Braftovi (encorafenib) • ABP 206 (nivolumab biosimilar)
7d
SWOG S1609: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov)
P2, N=798, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: May 2027 --> May 2026
Trial primary completion date
|
CD4 (CD4 Molecule)
|
PD-L1 overexpression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
13d
DREAMseq: Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma (clinicaltrials.gov)
P3, N=267, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2026 --> Dec 2026
Trial completion date
|
BRAF mutation • BRAF V600
|
THXID® BRAF Kit • cobas® 4800 BRAF V600 Mutation Test
|
Opdivo (nivolumab) • Mekinist (trametinib) • Yervoy (ipilimumab) • Tafinlar (dabrafenib) • ABP 206 (nivolumab biosimilar)
29d
SWOG S1609: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov)
P2, N=818, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
Trial completion date • Trial primary completion date
|
CD4 (CD4 Molecule)
|
PD-L1 overexpression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
1m
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (clinicaltrials.gov)
P1/2, N=54, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2026 --> May 2027
Trial completion date • Checkpoint inhibition • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
|
PIK3CA mutation • PTEN mutation
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Aliqopa (copanlisib) • ABP 206 (nivolumab biosimilar)
1m
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial (clinicaltrials.gov)
P2, N=50, Not yet recruiting, Fred Hutchinson Cancer Center
New P2 trial
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
PD-L1 expression • EGFR mutation • MSI-H/dMMR • ALK rearrangement
|
Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar)
1m
Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov)
P2/3, N=374, Not yet recruiting, National Cancer Institute (NCI)
New P2/3 trial
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Adcetris (brentuximab vedotin) • ABP 206 (nivolumab biosimilar)
1m
NRG-GY002: Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer (clinicaltrials.gov)
P2, N=26, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
Trial completion date
|
Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar)
2ms
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer (clinicaltrials.gov)
P2, N=143, Active, not recruiting, National Cancer Institute (NCI) | N=37 --> 143 | Trial completion date: Mar 2026 --> Mar 2027
Enrollment change • Trial completion date
|
CD4 (CD4 Molecule)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
2ms
S1826: Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma (clinicaltrials.gov)
P3, N=994, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
Trial completion date
|
Opdivo (nivolumab) • doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine • Neulasta (pegfilgrastim) • ABP 206 (nivolumab biosimilar) • Neupogen (filgrastim)
2ms
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial (clinicaltrials.gov)
P3, N=226, Recruiting, NRG Oncology | Initiation date: Oct 2025 --> Feb 2026
Trial initiation date
|
IL2 (Interleukin 2)
|
Opdivo (nivolumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • ABP 206 (nivolumab biosimilar)
Share via
